Company News: Elanco PRRS Vaccine; Newport Joins Boehringer Ingelheim

PRRS costs the swine industry $560 to $660 million annually, with the breeding herd costs accounting for 45% of the total industry cost. ( PORK )

Elanco Animal Health, a division of Eli Lilly and Company announces USDA licensing of Prevacent PRRS, a new modified-live respiratory vaccine that has been shown to be effective in the reduction of porcine reproductive and respiratory syndrome (PRRS), respiratory form, in piglets two weeks or older.

Industry leaders estimate that PRRS costs the swine industry $560 to $660 million annually, with the breeding herd costs accounting for 45% of the total industry cost. 1

"Elanco is excited to be able to provide producers and the entire swine industry with a new product that is proven effective against the respiratory form of PRRS," says Chris Chavis, senior director, Elanco North America Food Animal Business. "Not only is it safe to use in piglets two weeks or older, Prevacent PRRS has a demonstrated duration of immunity of 26 weeks for the respiratory form of PRRS."

The viral strain in Prevacent PRRS is highly relevant to today's swine operations so producers can be confident that they are getting effective protection against the respiratory form of PRRS for their piglets.

"The contemporary strain in Prevacent PRRS demonstrated cross protection against multiple difficult viral strains that may pose a threat to swine operations. Prevacent PRRS is a timely and effective solution for to meet the PRRS challenges producers are facing today," says Chavis.

Prevacent PRRS is a key part of Elanco's Full Value Pigs, which includes a complete portfolio of products that help to control specific enteric and respiratory diseases.

Visit for more information.


Newport Laboratories Joins Boehringer Ingelheim

Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minn., is officially part of Boehringer Ingelheim’s animal health business unit.

Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.

“Joining the BI family helps strengthen Newport Laboratories’ overall offering of disease-prevention products and diagnostic tests,” says Edgar Diaz, DVM, MS, president of Newport Laboratories. “Newport Laboratories is a great fit because we can enhance the protection that BI’s already robust line of vaccines offers to swine and cattle producers. With a focus on customer service and relationships that are at the core of who we are at Newport Laboratories, it’s refreshing to have the support of a larger company that shares those values.”

With solutions from both Newport Laboratories and Boehringer Ingelheim Health Management Center (HMC), which offers both diagnostic testing and field research services, BI now provides customers one of the most complete disease-prevention toolboxes in the livestock industry.

“Working together gives BI, Newport Laboratories and HMC the ability to give our customers a more well-rounded and comprehensive portfolio of products,” says Del Birkhofer, head of Boehringer Ingelheim’s U.S. Swine Business and Newport Laboratories. “We are now able to offer a broader range of animal health solutions, more resources, greater expertise and more innovation than we were even 18 months ago.”

For more information on Boehringer Ingelheim and Newport Laboratories, visit and